scholarly journals Breast Cancer Incidence Trends by Estrogen Receptor Status Among Asian American Ethnic Groups, 1990–2014

2020 ◽  
Vol 4 (2) ◽  
Author(s):  
Alyssa W Tuan ◽  
Brittny C Davis Lynn ◽  
Pavel Chernyavskiy ◽  
Mandi Yu ◽  
Scarlett L Gomez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Ethnic Groups ◽  
Asian American ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
Japanese Women ◽  
Incidence Trends ◽  
Er Positive ◽  
Er Status

Abstract Background Westernization and etiologic heterogeneity may play a role in the rising breast cancer incidence in Asian American (AA) women. We report breast cancer incidence in Asian-origin populations. Methods Using a specialized Surveillance, Epidemiology, and End Results-9 Plus API Database (1990–2014), we analyzed breast cancer incidence overall, by estrogen receptor (ER) status, and age group among non-Hispanic white (NHW) and AA women. We used age-period-cohort models to assess time trends and quantify heterogeneity by ER status, race and ethnicity, and age. Results Overall, breast cancer incidence increased for most AA ethnicities (Filipina: estimated annual percentage change [EAPC] = 0.96%/year, 95% confidence interval [CI] = 0.61% to 1.32%; South Asian: EAPC = 1.68%/year, 95% CI = 0.24% to 3.13%; Chinese: EAPC = 0.65%/year, 95% CI = 0.03% to 1.27%; Korean: EAPC = 2.55%/year, 95% CI = 0.13% to 5.02%; and Vietnamese women: EAPC = 0.88%/year, 95% CI = 0.37% to 1.38%); rates did not change for NHW (EAPC = -0.2%/year, 95% CI = -0.73% to 0.33%) or Japanese women (EAPC = 0.22%/year, 95% CI = -1.26% to 1.72%). For most AA ethnicities, ER-positive rates statistically significantly increased, whereas ER-negative rates statistically significantly decreased. Among older women, ER-positive rates were stable for NHW and Japanese women. ER-negative rates decreased fastest in NHW and Japanese women among both age groups. Conclusions Increasing ER-positive incidence is driving an increase overall for most AA women despite declining ER-negative incidence. The similar trends in NHW and Japanese women (vs other AA ethnic groups) highlight the need to better understand the influences of westernization and other etiologic factors on breast cancer incidence patterns in AA women. Heterogeneous trends among AA ethnicities underscore the importance of disaggregating AA data and studying how breast cancer differentially affects the growing populations of diverse AA ethnic groups.

scholarly journals Breast cancer incidence and estrogen receptor ? in normal mammary tissue?An epidemiologic study among Japanese women in Japan and Hawaii

2002 ◽  
Vol 97 (5) ◽  
pp. 685-687 ◽  
Author(s):  
James S. Lawson ◽  
Andrew S. Field ◽  
Dinh D. Tran ◽  
Jeffrey Killeen ◽  
Gertraud Maskarenic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
Epidemiologic Study ◽  
Japanese Women ◽  
Mammary Tissue ◽  
Normal Mammary Tissue

Breast cancer incidence trends in deprived and affluent Scottish women

2006 ◽  
Vol 103 (2) ◽  
pp. 233-238 ◽  
Author(s):  
Sylvia B. F. Brown ◽  
David J. Hole ◽  
Timothy G. Cooke
Keyword(s):  
Breast Cancer ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
Incidence Trends

Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome

2019 ◽  
Vol 177 (1) ◽  
pp. 77-91
Author(s):  
Cody Plasterer ◽  
Shirng-Wern Tsaih ◽  
Amy R. Peck ◽  
Inna Chervoneva ◽  
Caitlin O’Meara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
Estrogen Receptor Positive ◽  
Positive Breast Cancer

scholarly journals Phthalate Exposure and Breast Cancer Incidence: A Danish Nationwide Cohort Study

2019 ◽  
Vol 37 (21) ◽  
pp. 1800-1809 ◽  
Author(s):  
Thomas P. Ahern ◽  
Anne Broe ◽  
Timothy L. Lash ◽  
Deirdre P. Cronin-Fenton ◽  
Sinna Pilgaard Ulrichsen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Cancer Incidence ◽  
Dibutyl Phthalate ◽  
Cox Regression ◽  
Breast Cancer Incidence ◽  
Drug Products ◽  
Phthalate Exposure ◽  
Long Term Treatment ◽  
High Level

PURPOSE Phthalate exposure is ubiquitous and especially high among users of drug products formulated with phthalates. Some phthalates mimic estradiol and may promote breast cancer. Existing epidemiologic studies on this topic are small, mostly not prospective, and have given inconsistent results. We estimated associations between longitudinal phthalate exposures and breast cancer risk in a Danish nationwide cohort, using redeemed prescriptions for phthalate-containing drug products to measure exposure. METHODS We ascertained the phthalate content of drugs marketed in Denmark using an internal Danish Medicines Agency ingredient database. We enrolled a Danish nationwide cohort of 1.12 million women at risk for a first cancer diagnosis on January 1, 2005. By combining drug ingredient data with the Danish National Prescription registry, we characterized annual, cumulative phthalate exposure through redeemed prescriptions. We then fit multivariable Cox regression models to estimate associations between phthalate exposures and incident invasive breast carcinoma according to tumor estrogen receptor status. RESULTS Over 9.99 million woman-years of follow-up, most phthalate exposures were not associated with breast cancer incidence. High-level dibutyl phthalate exposure (≥ 10,000 cumulative mg) was associated with an approximately two-fold increase in the rate of estrogen receptor–positive breast cancer (hazard ratio, 1.9; 95% CI, 1.1 to 3.5), consistent with in vitro evidence for an estrogenic effect of this compound. Lower levels of dibutyl phthalate exposure were not associated with breast cancer incidence. CONCLUSION Our results suggest that women should avoid high-level exposure to dibutyl phthalate, such as through long-term treatment with pharmaceuticals formulated with dibutyl phthalate.

scholarly journals Age-Related Crossover in Breast Cancer Incidence Rates Between Black and White Ethnic Groups

2008 ◽  
Vol 100 (24) ◽  
pp. 1804-1814 ◽  
Author(s):  
William F. Anderson ◽  
Philip S. Rosenberg ◽  
Idan Menashe ◽  
Aya Mitani ◽  
Ruth M. Pfeiffer
Keyword(s):  
Breast Cancer ◽  
Ethnic Groups ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
Incidence Rates ◽  
Black And White ◽  
Age Related ◽  
White Ethnic ◽  
Cancer Incidence Rates

scholarly journals Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort

2010 ◽  
Vol 12 (1) ◽  
Author(s):  
Sarah F Marshall ◽  
Christina A Clarke ◽  
Dennis Deapen ◽  
Katherine Henderson ◽  
Joan Largent ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
Study Cohort ◽  
Incidence Trends

scholarly journals Prognostic Impact of Pregnancy After Breast Cancer According to Estrogen Receptor Status: A Multicenter Retrospective Study

2013 ◽  
Vol 31 (1) ◽  
pp. 73-79 ◽  
Author(s):  
Hatem A. Azim ◽  
Niels Kroman ◽  
Marianne Paesmans ◽  
Shari Gelber ◽  
Nicole Rotmensz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Pregnancy Outcome ◽  
Estrogen Receptor Status ◽  
Disease Free Survival ◽  
Prognostic Impact ◽  
Er Positive ◽  
The Impact ◽  
Disease Free ◽  
Er Status

Purpose We questioned the impact of pregnancy on disease-free survival (DFS) in women with history of breast cancer (BC) according to estrogen receptor (ER) status. Patients and Methods A multicenter, retrospective cohort study in which patients who became pregnant any time after BC were matched (1:3) to patients with BC with similar ER, nodal status, adjuvant therapy, age, and year of diagnosis. To adjust for guaranteed time bias, each nonpregnant patient had to have a disease-free interval at least equal to the time elapsing between BC diagnosis and date of conception of the matched pregnant one. The primary objective was DFS in patients with ER-positive BC. DFS in the ER-negative cohort, whole population, and overall survival (OS) were secondary objectives. Subgroup analyses included DFS according to pregnancy outcome and BC–pregnancy interval. With a two-sided α = 5% and β = 20%, 645 ER-positive patients were required to detect a hazard ratio (HR) = 0.65. Results A total of 333 pregnant patients and 874 matched nonpregnant patients were analyzed, of whom 686 patients had an ER-positive disease. No difference in DFS was observed between pregnant and nonpregnant patients in the ER-positive (HR = 0.91; 95% CI, 0.67 to 1.24, P = .55) or the ER-negative (HR = 0.75; 95% CI, 0.51 to 1.08, P = .12) cohorts. However, the pregnant group had better OS (HR = 0.72; 95% CI, 0.54 to 0.97, P = .03), with no interaction according to ER status (P = .11). Pregnancy outcome and BC–pregnancy interval did not seem to impact the risk of relapse. Conclusion Pregnancy after ER-positive BC does not seem to reduce the risk of BC recurrence.

scholarly journals Breast cancer incidence trends in Norway and estimates of overdiagnosis

2016 ◽  
Vol 24 (2) ◽  
pp. 83-91 ◽  
Author(s):  
Paula A van Luijt ◽  
Eveline AM Heijnsdijk ◽  
Nicolien T van Ravesteyn ◽  
Solveig Hofvind ◽  
Harry J de Koning
Keyword(s):  
Breast Cancer ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Cancer Incidence ◽  
Hormone Replacement ◽  
Breast Cancer Incidence ◽  
Cancer Registration ◽  
Sudden Increase ◽  
Incidence Trends ◽  
Registration Data

Objective Fluctuations in the incidence of breast cancer in Norway in the last three decades are partly explained by the use of hormone replacement therapy and mammography screening, but overdiagnosis has also been suggested as a cause. We assessed the trends in breast cancer incidence and overdiagnosis in Norway. Methods We calibrated our microsimulation model to Norwegian Cancer Registration data. The model takes into account the use of mammography (both within and outside the Norwegian Breast Cancer Screening Programme) and of hormone replacement therapy. We obtained a proper fit of breast cancer incidence in recent years, when assuming an increase in the background risk for breast cancer, and estimated overdiagnosis. Results We estimated a 2% overdiagnosis rate as a fraction of all cancers diagnosed in women aged 50–100, and a 3% overdiagnosis rate as a fraction of all cancers diagnosed in women aged 50–70 (i.e. screening age). If all of the increased incidence would be the result of the detection of slow growing tumours, these estimates were 7% and 11%, respectively. Conclusion Besides mammography and hormone replacement therapy use, additional risk factors contributed to the sudden increase in breast cancer incidence in Norway. Overdiagnosis estimates due to screening were within the range of international plausible estimates.

Sign in / Sign up

Export Citation Format

Share Document